Research findings have just been released for the PROTECT clinical trial which tested whether the disease-modifying therapy Teplizumab is able to delay type 1 diabetes (T1D) progression in those newly diagnosed. What is Teplizumab? Teplizumab is a therapy which has been shown to delay the progression from an early stage of T1D (Stage 2) to […]
JDRF Australia’s Career Support and Travel Grants for domestic and international travel are designed to support the next generation of type 1 diabetes (T1D) researchers. They allow early to mid-career researchers and allied health professionals to gain new skills, exchange knowledge, and establish connections and collaborations. We recently spoke to David de George, PhD student […]
In people newly diagnosed with type 1 diabetes (T1D) there is often a ‘honeymoon’ phase where some pancreatic beta cells are still able to produce insulin. Committed to improving the lives of those with T1D, JDRF has invested in several clinical studies under the Australasian Type 1 Diabetes Immunotherapy Collaborative (ATIC), investigating whether we can […]
Bringing researchers together to celebrate past and future type 1 diabetes breakthroughs On the 24th and 25th July 2023, JDRF Australia was delighted to host a research symposium: T1Decade of Research Progress – Past & Future to commemorate over a decade of achievements of the Type 1 Diabetes Clinical Research Network (T1DCRN). The T1DCRN is […]
JDRF Australia is delighted to announce the recipients of our 2023 PhD top-up scholarships: Rachel Hicks from Western Sydney University and Amanda Purcell from The Kolling Institute. The top-up scholarship is designed to support and encourage PhD students pursuing research in the field of type 1 diabetes (T1D) in line with JDRF’s mission – to […]